CNH Industrial signs agreement to acquire excavator manufacturer Sampierana S.p.A

With this acquisition, the Company will enhance its offering in the construction segment, gaining greater in-house capabilities, control over the value chain, and market share opportunities.

London, August 30, 2021

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces the execution of an agreement to purchase 90% of the capital stock of Sampierana S.p.A., a privately-owned Italian company that specializes in the development, manufacturing and commercialization of earthmoving machines, undercarriages and spare parts, and to obtain 100% control of the company over four years following closing of the transaction.

The debt and cash free consideration for the total transaction will be equal to €101.8 million subject to certain closing and post-closing adjustments. The consideration will be funded with available cash on hand of CNH Industrial. Closing is expected to occur in the fourth quarter of 2021, subject to the satisfaction of customary closing conditions.

“This latest strategic acquisition will further accelerate the profitable growth of our construction equipment business. Sampierana’s exceptional portfolio solidifies our presence in critical market segments and provides our dealers and customers access to industry-leading products backed by our brand, distribution, and manufacturing experience,” said Scott Wine, Chief Executive Officer of CNH Industrial. “I want to thank Stefano Pampalone, President Construction, and his team, both for driving this deal to completion and for their excellent work turning around our construction business, rightsizing the footprint and returning it to profitability – an impressive achievement given the challenging period.”

Recognized in the construction sector for its line of Eurocomach mini and midi excavators and for special undercarriages, Sampierana Group has recorded excellent performance year-over-year, particularly in Europe, and is acknowledged for its reliability, quality and innovative technology. Its broad product portfolio, high customization capacity, and existing electric power prototypes are an ideal fit with CNH Industrial’s customer-centric and sustainable approach, and substantially augment the Company’s in-house product and technology offerings.
This acquisition will enable CNH Industrial’s Construction Equipment business to integrate Eurocomach mini and midi excavators, Sampierana undercarriages and spare parts into its current product portfolio alongside those of its existing third-party OEM partners. It confirms CNH Industrial’s commitment to invest in and grow its construction equipment business, better positioning it in the high-demand mini and midi excavator market.

Sampierana is based in Italy with its headquarters and production sites. Furthermore, it operates a fully controlled subsidiary with production facilities in Kunshan, China.

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com

Sign up for corporate news alerts from the CNH Industrial Newsroom:
bit.ly/media-cnhindustrial-subscribe

Contacts:

Corporate Communications
Email: mediarelations@cnhind.com

Investor Relations
Email: investor.relations@cnhind.com

Attachment

In Thailand, Aerospace Engineers Turn Their Skills to COVID-19

BANGKOK – In Thailand, a team of aerospace engineers is using the high-tech skills they honed programming planes and satellites to run a simple but effective mapping website helping everyday volunteers reach those with COVID-19 who are falling through the cracks of a struggling public health care system.

Since going live in mid-July, jitasa.care has seen well over 10,000 households sign on, seeking assistance for everything from food to oxygen to an urgent ride to the hospital, most of them in the capital, Bangkok. About the same number of volunteers have signed up to help them.

“Jitasa” ties together the Thai words for “mind” and “volunteer.”

“In Thai it means … people who want to volunteer to do good deeds,” said Wasanchai Vongsantivanich, one of the lead developers.

He was surprised by how quickly the site took off. It got a big boost after someone shared the link with a popular local Facebook influencer who passed it on to his millions of followers.

“When it went widespread, people started to make use of this and a lot of volunteers subscribed by themselves [to] help each other, and that was fantastic and a wonderful thing that we see from the platform,” Wasanchai said.

The engineers’ efforts are part of an outpouring of help from Thais of all stripes who are volunteering their time and singular skills to take some of the load off the public health care system. The medical services are strained by the worst wave of infections to hit the country since the pandemic began.

Every day brings tens of thousands of new cases and hundreds of more deaths. Intensive care units in Bangkok are filling up, forcing some Thais to spend days hunting for a free hospital bed and the worst off to die at home before they find one.

‘People helping people’

Volunteers have played a vital role in meeting some of the shortfalls, said Pichit Siriwan, deputy director of relief and community health at the Thai Red Cross Society.

“They’re now very important. We need the volunteers’ help fighting against COVID-19 in Bangkok because of the rise in infections. Now the daily infection in the country is almost 20,000 cases … and almost half of them are in Bangkok,” he said, leaving hospitals in and around the city “overwhelmed.”

Pichit said the Thai Red Cross Society relies on thousands of volunteers itself, and that some of them have been using jitasa.care to find people with COVID-19 in need.

Wasanchai said the idea for site started with a backlog at crematoria burning the bodies of the newly dead, as per Buddhist tradition. A local volunteer group asked him and his colleagues to brainstorm ways to help families find available time slots.

By early July, so many people were dying of COVID-19 in the greater Bangkok area that the Buddhist temples with crematoria equipped to handle infected bodies safely were struggling to keep up. A colleague of Wasanchai’s who had just lost his grandmother to the virus had to call 19 temples before finding one that could take her.

Once the team came up with the idea of an interactive map of Thailand drawing on crowdsourced data to show people which temples had spare capacity, it was an easily leap to add community isolation centers with free beds, shops ready to fill oxygen tanks and more.

Just as helpful is the site’s ability to quickly connect the sick with people who want to help others. Anyone suffering from COVID-19 can sign in with a phone number, pin their location to the map, and post a note explaining their symptoms and what they need. Anyone who wants to help can sign on with their own phone number and contact them directly.

Those asking for assistance show up on the map as a bright red circle that grows bigger the longer they’ve been waiting. Their circle turns green when they start getting help, goes to gray once their needs have been met, then vanishes after a few days.

“Everyone can see the map, and they see their community and the area around them. Anyone around them who needs help, they just volunteer. If they think they can help [those] people, that household, they just contact and help,” Wasanchai said. “That is the simple idea — people helping people.”

Turning red to green

Sonskuln Thaomohr, who handles company registration records for the Commerce Ministry by day, has taken to jitasa.care with a passion.

Since coming across the site last month, he says he has responded to dozens of posts asking for help — taking blood oxygen level readings, dropping off food bundles to those self-isolating or helping seniors tap into public services by guiding them through online registration forms. Lately he has seen an increase in posts requesting anti-viral medicine.

“If I could do something to help the situation, I really want to do it,” said Sonskuln, whose close friend lost his mother to COVID-19 and blamed himself for having accidentally passed the virus on to her.

“I’m so sad for him, and that affects me personally because I don’t want any other of my friends or others to tell the sad story and blame themselves like that again,” he said.

Sonskuln likes that the site also lets volunteers communicate with one another and coordinate their efforts. But even then, they can sometimes be too late.

“We call it super red, which is the triage level,” he said. “That means they are in emergency state [and] need paramedic attention and … transfer to hospital ASAP. Those people are waiting inside their house and, to be honest, they are not in good shape at all. We have seen people dying — me too — laying on the floor.”

With other volunteer groups and even some government agencies signing in to jitasa.care to respond to posts for help, Wasanchai said, most of Bangkok’s red circles are turning green. Most of those on the site still waiting for help are now to the south and southeast of the capital.

After climbing steadily for more than four months, new daily infection numbers for the country have also started to level off and dip a bit in the past two weeks, convincing the government to start easing lockdown rules that have crippled the economy.

But Pichit, at Thai Red Cross Society, warned that the latest trend could be an artifact of less testing and said infection numbers were still rising in some provinces in the south and northeast of Thailand, so that health care professionals and volunteers alike would have to stay vigilant.

“The more you test, the more you find, so we still need to be aware that this decrease in number may be due to decreased tests,” he said. “So, we should keep an eye on it.”

Source: Voice of America

Laos posts 155 new Covid-19 cases, two new deaths

Some 155 new Covid-19 cases have been recorded nationwide over the past 24 hours with 140 classified as imported cases and 15 as local transmissions, according to Director General of the Department of Communicable Disease Control, Ministry of Health, Dr Rattanaxay Phetsouvanh.

Two new deaths were reported over the past 24 hours in Savannakhet raising the total in the country to 14.

The imported cases, dominated by migrant workers returning from neighboring countries, were identified in Champassak 53, Saravan 48, Savannakhet 19, Khammuan 14, Vientiane 5 and Luang Prabang 1.

The local infections were reported in Savannaket 9, Bokeo 3 and one each in Luang Namtha, Saravan and Vientiane (province).

Laos’s total of Covid-19 infections has reached 14,816 including 5,040 active cases and 14 deaths.

Source: Lao News Agency

Overseas Chinese Association Laos donates US$20,000 for Henan’s flood relief efforts

On Aug 27, Overseas Chinese Association Laos represented by its president Lengsavanvaly presented US$20,000 to Chinese Embassy in Vientiane to support flood relief efforts in Henan Province of China.

Henan was hit by torrential rains starting on July 16, according to Xinhua News Agency.

More than 14.81 million people in 150 county-level regions were affected by the downpours. About 1.08 million hectares of crops were damaged, and over 35,300 houses collapsed across the province, with a direct economic loss of over 133.7 billion yuan, official data shows.

Over the past months, the Overseas Chinese Association Laos has actively contributed to the Covid-19 fight in the Lao PDR by donating medical supplies and using its premises in Chanthaboury district, Vientiane as a Covid-19 vaccination site. Over 51,000 people have been vaccinated at the site.

Source: Lao News Agency

Distribution of Etesevimab/JS016 in the US Reopened

SHANGHAI, China, Aug. 29, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”), alongside the Office of the Assistant Secretary for Preparedness and Response, has resumed the shipment and distribution of etesevimab and bamlanivimab administered together (the “Therapy”), according to the company’s global partner Eli Lilly and Company (NYSE: LLY). Direct ordering will be available to authorized states in the U.S. effective immediately.

The decision to resume distribution aligns with the FDA’s issuance of an updated fact sheet (the “Fact Sheet”) and a revised letter of authorization for etesevimab and bamlanivimab together. These include a revised limitation of authorized use, only allowing use in the states, territories, and U.S. jurisdictions with a low prevalence of variants that are resistant to treatment with the antibodies.

The Delta variant (the “Delta”) currently accounts for nearly 96 percent of all identified COVID-19 cases in the U.S. As shown in revisions to the Fact Sheet, pseudovirus and authentic virus studies demonstrate that etesevimab and bamlanivimab together retained neutralization activity against the Alpha variant and the Delta.

Over the last several months, prevalence of variants varies by state, region and even country and can change rapidly. As variants continue to evolve and their patterns of transmission and prevalence shift, Eli Lilly and Company (“Lilly”), a partner of the Company, will continue to work with governments and regulators worldwide to ensure the Therapy is available to appropriate patients.

About Etesevimab (JS016/LY-CoV016)
Etesevimab is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from the Company after it was jointly developed by the Company and the Institute of Microbiology of Chinese Academy of Science. The Company leads development in Greater China (including mainland China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the Taiwan region), while Lilly leads development in the rest of the world.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of the Chinese Academy of Sciences and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) from the US FDA in February 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at a high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+86 021-6105 8800

195 new cases of Covid -19 recorded

Some 195 new cases of Covid-19 have been recorded nationwide over the past 24 hours with 98 classified as local transmissions and 97 as imported cases.

The local infections were reported in Savannakhet 57, Bokeo 15, Vientiane 12, Khammuan 5, Luang Prabang 4, Luang Namtha 2, Oudomxay 2, and Vientiane (province) 1.

The imported cases, dominated by migrant workers returning from neighbouring countries, were identified in Champassak 71, Khammuan 9, Borikhamxay 7, Saravan 6, Xayaboury 3, and Vientiane 1.

Laos’ total of Covid-19 infections has reached 14,641 including 12 deaths and 4,901 active cases.

The past 24 hours witnessed Thailand logging 17,984 new cases and 292 new deaths, Myanmar recording 2,932 new cases and 109 new deaths, Vietnam documenting 12,103 new cases and 352 new deaths, and Cambodia posting 401 new cases and 12 new deaths.

Source: Lao News Agency